Harvard Bioscience, Inc.
HBIO
$0.3769
-$0.013-3.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -16.14% | -13.15% | -11.36% | -6.76% | -0.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -16.14% | -13.15% | -11.36% | -6.76% | -0.96% |
| Cost of Revenue | -14.25% | -11.31% | -13.51% | -9.85% | -7.81% |
| Gross Profit | -17.45% | -14.39% | -9.78% | -4.47% | 4.40% |
| SG&A Expenses | -6.63% | -4.19% | -2.10% | -3.29% | -3.77% |
| Depreciation & Amortization | -4.89% | -6.64% | -9.48% | -9.50% | -9.75% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.50% | -6.31% | -6.49% | -5.44% | -5.89% |
| Operating Income | -307.94% | -252.25% | -341.67% | -6,868.18% | 175.79% |
| Income Before Tax | -356.38% | -469.64% | -45.67% | -764.47% | 72.15% |
| Income Tax Expenses | -13.85% | -3.81% | 219.64% | -54.34% | 154.90% |
| Earnings from Continuing Operations | -263.25% | -336.44% | -96.68% | -333.52% | 64.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -263.25% | -336.44% | -96.68% | -333.52% | 64.11% |
| EBIT | -307.94% | -252.25% | -341.67% | -6,868.18% | 175.79% |
| EBITDA | -79.26% | -76.63% | -65.14% | -25.60% | 121.64% |
| EPS Basic | -256.95% | -326.79% | -90.52% | -326.26% | 65.15% |
| Normalized Basic EPS | -490.67% | -3,230.61% | -134.69% | -162.17% | 70.97% |
| EPS Diluted | -238.04% | -302.30% | -87.81% | -292.56% | 63.12% |
| Normalized Diluted EPS | -488.55% | -3,100.00% | -133.69% | -165.68% | 70.44% |
| Average Basic Shares Outstanding | 2.53% | 2.33% | 2.42% | 2.39% | 2.17% |
| Average Diluted Shares Outstanding | 2.59% | 1.93% | 2.02% | 1.23% | 1.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |